Report on short-term side effects of treatments with (177)Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours

PURPOSE: Treatment with the radiolabelled somatostatin analogue (177)Lu-octreotate results in tumour remission in 47% of patients with gastroenteropancreatic neuroendocrine tumours. Adding capecitabine to (177)Lu-octreotate, as a radio-sensitiser, may enhance these anti-tumour effects. We now presen...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: van Essen, Martijn, Krenning, Eric P., Kam, Boen L., de Herder, Wouter W., van Aken, Maarten O., Kwekkeboom, Dik J.
Format: Artigo
Jezik:Inglês
Izdano: Springer Berlin Heidelberg 2008
Teme:
Original Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2668587/
https://ncbi.nlm.nih.gov/pubmed/18188559
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00259-007-0688-7
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items